Compare Charles River Laboratories Intl. Inc (CRL) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Infosys Limited — how do they compare? Charles River Laboratories Intl. Inc trades at $299.03 (market cap $14.23B), while Infosys Limited trades at $10.81 (market cap $41.74B). The key difference: Infosys Limited is far larger — about 2.9× Charles River Laboratories Intl. Inc's market cap, and Infosys Limited pays a 4.89% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Infosys Limited for 27 Days on average.
| CRL | INFY | |
|---|---|---|
Market Cap | $14.23B | $41.74B |
Volume | 1,176,885 | 31,354,285 |
Sector | Health | Technology |
52-Week High | $310.77 | $20.22 |
52-Week Low | $149.93 | $10.49 |
Typical Hold Time | 33 Days | 27 Days |
Enterprise Value | $17.06B | $39.48B |
Dividend Yield | — | 4.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
INFY trades at $10.78, up 2.18% today, with a bearish technical signal from moving averages. The company reported revenue of $19.28B in 2025 with a net income margin of 16.37%, and recent earnings show mixed results with a beat in Q1 2026 but a miss in Q2 2026. Positive news includes strategic AI collaborations with Columbia University and ABN Amro, highlighting growth initiatives in technology services.
The outlook is cautiously optimistic with a consensus price target of $11.48, offering potential upside. Risks include competitive pressures in IT services and volatile cash flow trends, with net cash flow turning negative in 2026. Analyst sentiment is mixed, with 35% buy ratings, but institutional activity shows increased holdings, supporting a stable foundation for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
